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Novelty Statement 
 
a) Adolescents with type 1 diabetes frequently experience diabetic 
ketoacidosis. However, how much treating this condition costs in this 
age group remain unknown in the UK 
 
b) We used the 2014 national survey dataset to conducted a novel, 
‘bottom-up’ approach to cost analysis 
 
c) Our data suggest that the average cost of an episode of diabetic 
ketoacidosis in an adolescent in the UK in 2014 was £1387. 
 
d) Use of the BSPED guideline was associated with significant £762 
reduction in costs.  
  
Abstract 
 
Aims 
Adolescents with type 1 diabetes commonly experience episodes of diabetic 
ketoacidosis (DKA).  In 2014 we conducted a nationwide survey on the 
management of DKA in young people. The survey reported how individual 
adolescents with diabetes were managed. However, costs of treating DKA 
were not reported.  
Methods 
Using this mixed population sample of adolescents we used a ‘bottom up’ 
approach to cost analysis aiming to determine the total expense associated 
with treating DKA. The data were derived using the information from the 
national UK survey of 71 individuals, collected via questionnaires sent to 
specialist paediatric diabetes services in England and Wales. 
Results 
Several assumptions had to be made when analysing the data because the 
initial survey collection tool was not designed with a health economic model in 
mind. The mean time to resolution of DKA was 15.0hrs (95% CI: 13.2, 16.8) 
and the mean total length of stay was 2.4 days (95% CI: 1.9, 3.0). Based on 
the individual patient data and using the British Society of Paediatric 
Endocrinology and Diabetes guidelines, the cost analysis shows that for this 
cohort, the average cost for an episode of DKA was £1387 [95% confidence 
interval (CI): £1120, £1653]. Regression analysis showed a significant cost 
saving of £762 [£140, £1574] (p=0.04) among those treated using BSPED 
guidelines. 
Conclusion 
We have used a bottom up approach to calculate the costs of an episode of 
DKA in adolescents. These data suggest that following treatment guidelines 
can significantly lower the costs for managing episodes of DKA.  
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Introduction 
Diabetic ketoacidosis (DKA) is a frequently encountered metabolic emergency 
in adolescents with type 1 diabetes [1]. Recent work has shown that each 
episode of DKA in an adult in the UK in 2014 cost the National Health Service 
£2064 per person (95% CI: £1800, 2563) [2]. However, the costs of DKA in 
young people remain unknown.  
 
In 2014 a national survey was carried out in the UK looking at the 
management of DKA in adolescents and young adults aged between 11 and 
22 years old [3]. This survey looked at outcomes of a convenience sample of 
young people with diabetes aged <18 years old (mean age 14.9 years, range 
11 - 18) presenting with DKA over a 7 month period. 56 out of 185 paediatric 
diabetes services returned data on 120 admissions looking at all aspects of 
their care during the acute hospital admission [3]. Each admission was for a 
separate individual. The demographic data of these individuals have been 
described previously [3]. We used this dataset to conduct an analysis to 
assess how much it cost to treat DKA in young people in the UK in 2014 
 
Methods 
Our analysis was identical to that used in our previous work on the costs of 
adult DKA [2]. The cost analysis followed a bottom up approach and was 
based on an aggregation of individual-level factors collected as part of the 
questionnaire, and informed by the 2013 British Society of Paediatric 
Endocrinology and Diabetes (BSPED) guidelines [4]. This is the version of the 
guideline that would have been used for those presenting with DKA at the 
time of the data collection. The main components of our cost estimates 
included laboratory and diagnostic assessments, physician and nurse 
contacts as well as drug dosages during the early phase of the DKA 
admission. Following the resolution of DKA per diem ward costs were used. 
We used the questionnaires to estimate the quantity of diagnostic tests, as 
well as time from admission to DKA resolution and time to discharge. The 
times taken by healthcare were based on expert opinion. Our costing 
assumptions are shown below, and individual prices are shown in Table 1.  
 Individuals were assessed on admissions for 15 minutes by a junior 
doctor. 
 On admission, a nurse took 15 minutes to collect the urine and blood 
samples.  
 Everyone received intravenous insulin according to BSPED guidelines 
every hour from admission to DKA resolution. This required 5 minutes 
of junior doctor time and 15 minutes of nurse time per hour. 
 For dosing purposes, individuals were assumed to weigh an average of 
55kg – the mean weight at the 50th centile of boys (56kg) and girls 
(54kg) aged 14.9 years [5]. 
 It took 30 minutes of nurse time to be assessed by members of the 
paediatric diabetes specialist team. 
 Table 2 shows the location of care during the DKA phase as recorded 
in the individual questionnaires. It was assumed that individuals were 
transferred to a general paediatric ward when their DKA had resolved 
for the remainder of their hospital stay.  
 If there were more than one treatment location recorded (7% of 
responses), we assumed treatment occurred in the more intensive 
location. 
 Unlike adults, there is no target for the length of time young people 
spend in an emergency department, thus for those treated in Accident 
and Emergency or a paediatric assessment unit, we assumed a 
maximum time of 4 hours after which they were equally likely to be 
transferred to paediatric intensive care unit or the general ward until 
DKA resolution. 
 We used published data to calculate the per diem costs for time on the 
acute wards and time spent in the general ward according to the best 
practice tariff [6,7]. 
 We assumed 30 minutes of nurse time for a follow-up visit from the 
paediatric specialist diabetes team. 
 
A bottom up costing approach involves resource utilisation at the patient or 
individual level. The patient level utilisation data are aggregated to identify 
types of resources used in order to calculate overall costs. In contrast to 
bottom up approach, top down costing first calculates the total costs of the 
service at the organisational, provider or departmental level and then 
disaggregates the total costs to the department or the units of service or 
products [8].  
 
We used the sum of individual components to calculate the total costs. These 
included the costs of initial assessments by the medical and nursing staff as 
well as diagnostic/laboratory tests, insulin and other drugs during the acute 
DKA phase. In addition ward per diem costs during the acute phase of 
treatment, and during recovery, as well as a follow-up visit post admission 
were estimated. We did not include costs associated with the consequences 
of the episode or treatment of any precipitating factors. We also did not 
include costs associated with any follow-up beyond an initial visit from a 
member of the paediatric diabetes specialist team.  
 
Missing data and imputation  
We used multiple imputation methods to infer values for missing values, 
assuming values were missing completely at random (MCAR) [2]. This was 
because a number of variables had a high proportion of missing values. We 
performed predictive mean matching (PMM) using the Multivariate Imputation 
by Chained Equations Package in R statistical software (version 3.4.2) [9]. 
This method estimates a regression model for each variable with missing 
values, and replaces each missing value with the value of the record with the 
closest match on the regressed predictors [10]. The regression model is used 
to estimate the similarity of the record with other non-missing observations 
rather than the missing value itself. Table 3 in the online supplementary 
material shows a summary of the questionnaire data as well as the variables 
with imputed values. Table 4 lists the costs by individual component. We did 
not impute non-continuous variables including flags indicating any particular 
imaging modality or blood test. Rather, we imputed the continuously 
distributed sub-totals for the individual components i.e. nursing and physician 
times; laboratory or other diagnostic tests; insulin and other drugs; and ward 
per diems. We used the sum of these components to estimate total cost. This 
allowed us to avoid using strong assumptions about the distribution of non-
normal parameters but rather as much as possible used the estimated total 
cost to be based on observed values. A comparison of the observed and 
imputed total costs is shown in Figure 1. 
 
Following data imputation, we tested the fit of different theoretical distributions 
to inform future modelling efforts. We tested gamma and log-normal 
distributions using the fitdistrplus package and selected the preferred 
distribution on the basis of the Bayesian Information Criterion (BIC).  
 
Predictors of cost and length of stay  
We used linear regression to test a number of predictors of cost and length-of-
stay (LOS). These included gender, age, number of prior admissions with 
DKA, flags suggesting hypoglycaemia following resolution of DKA, and 
whether DKA treatment followed BSPED guidelines. 
 
Clinical care staff  
We sought expert opinion from a consultant in paediatric diabetes medicine 
(VD) and a paediatric diabetes specialist nurse (PH) to determine the amount 
of time spent by medical, nursing and other clinical care staff in managing 
those individuals presenting with DKA. We determined the following minimum 
times that would be spent by induvial members of the clinical staff. A full list of 
clinical staff, their allocated time, and any procedures and is provided in 
Appendix 1 in the on line supplementary material. This was constructed by the 
two authors (VD and PH) using the BSPED DKA guideline [4].  
 
Similarly, we determined the hourly wage rages of a range of different staff to 
enable the determination of any costs associated with clinical care staff time. 
Sources of salaries and other costs are provided in Table 1. 
 
Costs of DKA were only considered from the time of admission to the 
resolution of DKA. This allowed us to determine the impact of DKA alone on 
the NHS and did not take into the account and other factors, such as 
comorbidities or individual circumstance. These may have led to higher 
overall costs due to lengthier hospital stays than would be the case with 
treating DKA alone.  
 
 
Results 
The mean cost per episode of DKA was £1387 [95% confidence interval (CI): 
£1120, 1653], including nursing and medical time, diagnostic and laboratory 
assessments, intravenous insulin, and ward per diems. The mean time to 
resolution of DKA was 15.0hrs (95% CI: 13.2, 16.8) and the mean total length 
of stay was 2.4 days (95% CI: 1.9, 3.0).  
 
We found that a theoretical log normal distribution, with a log mean of 6.999 
and standard error of 0.08, had the best fit with observed (imputed) 
distribution of total costs (BIC 1145.1) compared with gamma distribution (BIC 
1161.4). Figure 2 shows the empirical and theoretical distributions. 
 
The distribution of individuals by treatment area is shown in Table 2. The 
majority were treated in high dependency units and general wards.  
 Predictors of time to resolution, cost and length of stay  
The presence of one or more precipitating factors increased the mean time to 
resolution by 6.8h (p=0.001). Resolution time also increased with year of 
diagnosis, by 0.5h per year (p=0.01). An episode of hypoglycemia increased 
the length of stay by 1.6 days (p=0.01). Following the BSPED guidelines was 
associated with a significant reduction in total costs, by £762 [95% CI, £140, 
£1574] (p=0.04). This is shown in Figure 3 in the supplementary materials. 
 
Transfer to HDU 
Using the BSPED guidelines, we determined the number of individuals who 
should have been transferred to an HDU. By observing two important factors 
(pH and age) we determined that according to the BSPED guidelines 46% of 
those with DKA should have been treated in an High Dependency Unit (HDU) 
or Intensive Therapy Unit (ITU). However, only 26% were actually treated in 
HDU or ITU.  
 
Cost impact of precipitating causes 
We also looked at precipitating factors for DKA. The nationally collected data 
used in this analysis showed that 62 (87%) of individuals provided information 
on their precipitating factors. Of those, 32 (52%) were had poor concordance 
with their diabetes treatment; seven (11%) had issues with insulin pump or 
device failures; and 23 (37%) were due a combination of other acute and non-
acute illnesses. The granularity of these individual patient level data are what 
has differentiated the present work from previous studies. 
 
Discussion  
This study has shown that in 2014, the average cost of treating an episode of 
diabetic ketoacidosis in an adolescent in the UK was £1387 (95% CI: £1120, 
£1653). This compares to a cost of £2064 (95%CI: 1800, 2563) for adults [2]. 
In addition, we have shown that following the BSPED guideline is associated 
with a £762 reduction in costs.  
 
We acknowledge that the data collected as part of the 2014 national survey 
were not specifically collected for to allow for detailed health economic 
analyses. However we were able to use the 2013 BSPED DKA guideline to 
identify a treatment pathway which was used by the majority of hospitals who 
returned data [4]. In addition, using expert opinion, we were able to determine 
the time required by individual staff types as each step in the management 
pathway. Furthermore, we were able to determine the impact of a range of 
physiological results upon the resolution of DKA. This allowed us to be more 
precise in determining the costs associated with the treatment of DKA than 
has been done previously.  
 
Admissions for DKA are common in individuals under 18 years old, with 
reported rates of 5% per annum in Austria and Germany, 6.4% in the UK and 
7.1% in the USA [11,12]. Recent data has suggested that – in the UK – that 
the rate of DKA has remained unchanged between 2012 and 2015 at just over 
28% of all admissions to hospital, with about a quarter of these being children 
with newly diagnosed type 1 diabetes [13]. Most episodes occur in children 
known to have diabetes during or after transition from the adolescent to the 
adult service [13,14].  
 Costs vary with data from the US in 2004 to 2014 estimating that the numbers 
of admission in the US rose by 62%, and the costs per episode of DKA had 
also risen from  $18,987 (£15,112) to $26,566 (£20,178) [15]. However, these 
were costs for all DKA admissions. Costs for children – as with the UK data – 
have been calculated as lower than adults at between $7,429 (£5,642) and 
$10,881 (£8,264) [16]. Data from Germany did not give estimates of cost per 
episode, but showed that annual costs of care for individuals who had 
episodes of DKA were increased compared to those who did not – cost ratio 
of 2.2 (95%CI 2.1-2.3) for those with just 1 episode of DKA, and 3.6 (95%CI 
3.1-4.1) for those with more than one [12].  
  
Cost of DKA  
Direct healthcare costs 
This study is one of the few to present the costs of treating DKA in 
adolescents from a secondary care perspective. A costing statement from the 
UK National Institute for Health and Care Excellence suggested that the 
prevention of each DKA admission saved a potential £1000-1400 – a figure 
derived from NHS England's guide to the enhanced tariff option for 2015–16 
[17]. Our data are consistent with this. One of the main reasons why the 
average costs for the adolescent DKA population were lower than a similar 
analysis done for the adult population (£1387 vs £2064), is possibly the length 
of stay [2].  The median [interquartile range (IQR)] length of stay for 
adolescents was 1.85 (1.00, 2.74) days, with a mean (SD) of 2.35 (2.3) days, 
and in the adults, it was 2.0 (1.12, 2.67) days, with a mean (SD) of 2.53 (2.4) 
days. Whilst this was not statistically significant (P = 0.3), a difference in 
median length of stay of 12 hours may have been sufficient to account for the 
difference. In addition, the care setting was different, with only 2.9% of the 
adolescent population being in the expensive intensive care unit, compared to 
12.5% of the adult population [3,18]. Not transferring these individuals could 
have resulted in a lower cost of DKA treatment. Among other plausible 
reasons, the most significant factor to consider on this aspect would be 
shortage or unavailability of beds. As a result, institutional arrangement and 
capacity constraints could have been the influential factors while assessing 
costs. 
 
Those who were treated with the BSPED protocol incurred a significantly 
lower cost than those who were not. This may be because following the 
guideline minimises the room for errors, and determines the treatment targets. 
Indeed, recent work has shown that following guidelines for the management 
of DKA is associated with a decrease in length of stay and better prescribing, 
which are important determinants of cost [19].  
 
These potential cost savings may need to be offset against the costs of nurse 
time, or of those providing education in terms of admissions avoidance [20].  
These costs were not factored into the current model, because our focus was 
on the cost of an episode of DKA, not on prevention or avoidance. In addition, 
we had no data on what contact had been made by diabetes teams with 
individual patients prior to admission. 
 
Productivity losses 
By using forecasts of the population of people with diabetes increasing over 
the coming years and data on incidence rates of DKA, it is possible to assign 
values to future costs of DKA treatment. This is particularly possible using the 
crude prevalence rate of type 1 diabetes mentioned in the 2017 UK National 
Diabetes Paediatric Audit [21]. This is given as 195.4 per 100,000 of the 
general population in those aged 0-15 [21]. The crude prevalence rate of DKA 
events in the UK was 20.1% of DKA (not at diagnosis) and 7.1% for DKA at 
diagnosis of type 1 diabetes [13]. From this figure we can multiply the average 
cost for DKA and obtain a figure allowing us to determine the economic 
burden of the disease for the years to come. What is not taken into account by 
these data is the loss of productivity of the caregivers / parents whilst their 
child is in hospital, and thus the overall cost to society is likely to be 
substantial.  
 
We acknowledge that there are several limitations to our data. We had to 
make several assumptions because the data collected were not in a form that 
was easily usable for health economic analysis. In addition, these data came 
from a retrospective convenience sample. In addition, we did not add on costs 
associated with the treatments of co-morbidities – because these were so 
disparate and because the sample size was too small to make generalised 
assumptions about them. Neither did we include further salary costs (e.g. 
employers ‘on costs’). We could not cost for recurrent readmissions because 
none of the people included had a recurrent admission. There are already 
data of the costs of overall annual care in those with multiple admissions 
[12,22]. However, the major strengths of our data are that it was collected 
from across the UK, and that data were available from most for all stages of 
the patient journey – admission to resolution of DKA – from which appropriate 
calculations could be made.  
 
In summary, the average cost of an episode of DKA in an adolescent in the 
UK in 2014 was £1387 (95% CI: £1120, £1653). Whilst many assumptions 
were made to make these calculations, as the number of people with diabetes 
increases, it is likely that the number of people admitted with DKA will also 
increase. In addition, it is likely that the true costs of an episode of DKA are 
much higher given these many assumptions. We believe that funders can 
plan for future costs associated with this potentially life-threatening medical 
emergency using these data. 
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Legends to Tables, Figure and Appendices 
 
Table 1 - Cost components - unit prices  
Table 2 - Distribution of individuals by treatment area, with the differences in 
costs for the BSPED vs non-BSPED groups 
 
Figure 1 - Comparison of the observed and imputed total costs 
Figure 2 – A Log-normal distribution best fit the imputed total costs 
 
Online supplementary data 
 
Table 3 – Data collection with percentage of missing data and imputed data 
Table 4 – Costs by component 
Figure 3 – The differences in costs for the BSPED vs non-BSPED groups 
 
Appendix 1 - A full list of allocated time, procedure and clinical staff needed to 
treat an episode of DKA  
Table 1 
Cost Component 
Unit 
Cost (£) 
Hospital facilities  
Level 1: General Ward – per day 428.49* 
Level 2: HDU – per day 889.14* 
Level 3: ITU – per day 2004.45* 
Acute Medical Unit (AMU) - per day 428.49* 
A&E – per day 2552.00* 
Other wards – per day 428.49* 
Variable  
Healthcare staff (per hour)  
Staff Nurse (Band 6) 13.32** 
Specialist Registrar (Middle band) 23.76Ƭ 
Junior Doctor 14.39Ƭ 
Diabetes Specialist Nurse (Band 6) 16.70** 
Variable  
Investigations  
X-Ray 25.00§ 
Laboratory blood tests 1.00§ 
Electrocardiogram (ECG) 32.00§ 
 Urine test strip (per 10) 4.30¥ 
 Intravenous insulin 5.24∞ 
1 litre 0.9% sodium chloride solution with potassium 2.20¶ 
* Data taken from Reference [6], ** Data taken from Reference [23], Ƭ Data 
taken from [24], § Data taken from [25], ¥ Data taken from [26], ∞ Data taken 
from [27], ¶ Data taken from  [28] 
Table 2  
 
Treatment Area Distribution (%) Follow BSPED 
(n=60) 
Don’t follow  
BSPED  
(n=11) 
High Dependency Unit 47 27 
General ward 22 18 
Accident & Emergency 22 0 
Assumption made 0 45* 
Acute Medical Unit 5 9 
Intensive Care Unit 3 0 
Other 2 0 
* assumption made for 5 cases here which reported treatment in HDU, AMU or ITU 
along with A&E. 
 
Total costs (mean) [95% CI] £1294 [1065, 1523] £2151 [869, 3432] 
   
Mean difference  
95 percent confidence interval    £140, £1574 
 
